The Independent Uganda: You get the Truth we Pay the Price
Cipla Quality Chemical Industries Limited has been approved to market antiretrovirals and malaria medicines to the ECOWAS and ZAZIBONA regions
Kampala, Uganda | Julius Businge | Cipla Quality Chemical Industries Limited (CiplaQCIL) recently acquired approval to manufacture and distribute lifesaving medicines to the ECOWAS and ZAZIBONA regions in Africa.
The company was approved to market antiretrovirals and malaria medicines such as efavirenz 600 mg; lamivudine 300 mg; tenofovir 300 mg Artemether 20 mg; lumefantrine 120 mg tablets, and tenofovir 300mg/lamivudine 300mg/dolutegravir 50mg (TLD) tablets.
The medicines will be manufactured and delivered to the region effective immediately.
In a media release dated Apr.22, CiplaQCIL’s Chief Executive Officer, Nevin Bradford said, for the first time, a manufacturer from East Africa has received approval to supply lifesaving medicines to the ECOWAS regulatory authority.
“The approval from the regulatory authority not only bestows a vote of confidence in CiplaQCIL but also in Uganda’s pharmaceutical industry as a whole,” Bradford said.
The approval opens doors for CiplaQCIL to gain entry into new markets such as Benin, Burkina Faso, Cabo Verde, Cote d’Ivoire, The Gambia, Guinea, Guinea Bissau, Mali, Niger, Nigeria, Ghana, Senegal, Sierra Leone, Togo, Liberia, Namibia, Malawi, Zambia, Zimbabwe, Mozambique, Botswana, the Democratic Republic of the Congo, Tanzania and South Africa.
The company recently upgraded its manufacturing facility to be able to meet the increased volumes following this approval.
“We are proud to be able to produce quality, affordable medicine in Africa, for Africa in line with our ethos of caring for life,” Bradford said.
